Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Genetics, Faculty of Advanced Technologies in Medicine, Golestan University of Medical Science, Gorgan, Iran.
Pathol Res Pract. 2023 Nov;251:154903. doi: 10.1016/j.prp.2023.154903. Epub 2023 Oct 21.
MicroRNA-3613 (hsa-miR-3613-5p), a biomarker with a dual role as an oncogenic or tumor suppressor, is associated with different types of cancer. This study aimed to determine the correlation between the hsa-miR-3613-5p gene expression and Kidney renal clear cell carcinoma (KIRC). Utilizing several bioinformatics tools, we examined the expression level and clinicopathological value of hsa-miR-3613-5p in patients with KIRC compared to normal tissues. Other bioinformatic measures, including survival analysis, diagnostic merit of hsa-miR-3613-5p, downstream target prediction, potential upstream lncRNAs, network construction, and functional enrichment analysis of hsa-miR-3613-5p, were performed. We observed that overexpression of hsa-miR-3613-5p in KIRC tissues had valuable diagnostic merit and was significantly correlated with the poor overall survival of KIRC patients. We also realized a correlation between abnormal expression of hsa-miR-3613-5p and several clinical parameters such as pathological stage, race, age, and histological grades in patients with KIRC. Moreover, we constructed the most potential regulatory network of hsa-miR-3613-5p in KIRC with 17 different axes, including four pseudogenes, two lncRNAs, and three mRNAs. Besides, we uncovered six variants in the mature form of hsa-miR-3613-5p. Finally, pathway enrichment analysis demonstrated that the top-ranked pathways for hsa-miR-3613-5p are cell cycle, cell adhesion molecules (CAMs), and hepatocellular carcinoma pathways. The present report suggests that the higher expression of hsa-miR-3613-5p is associated with the progression of KIRC. Therefore, it may be considered a valuable indicator for the early detection, risk stratification, and targeted treatment of patients with KIRC.
微小 RNA-3613（hsa-miR-3613-5p）是一种具有致癌或肿瘤抑制双重作用的生物标志物，与多种类型的癌症有关。本研究旨在确定 hsa-miR-3613-5p 基因表达与肾透明细胞癌（KIRC）之间的相关性。利用几种生物信息学工具，我们比较了 KIRC 患者与正常组织中 hsa-miR-3613-5p 的表达水平和临床病理价值。其他生物信息学措施，包括 hsa-miR-3613-5p 的生存分析、诊断价值、下游靶基因预测、潜在的上游 lncRNA、网络构建以及 hsa-miR-3613-5p 的功能富集分析也进行了研究。我们观察到，KIRC 组织中 hsa-miR-3613-5p 的过表达具有有价值的诊断价值，并且与 KIRC 患者的总体生存不良显著相关。我们还发现 hsa-miR-3613-5p 的异常表达与 KIRC 患者的几个临床参数（如病理分期、种族、年龄和组织学分级）之间存在相关性。此外，我们构建了 KIRC 中 hsa-miR-3613-5p 最具潜力的调控网络，该网络包含 17 个不同的轴，包括四个假基因、两个 lncRNA 和三个 mRNA。此外，我们还发现了 hsa-miR-3613-5p 成熟形式的六个变体。最后，通路富集分析表明，hsa-miR-3613-5p 的排名最高的通路是细胞周期、细胞黏附分子（CAMs）和肝细胞癌通路。本报告表明，hsa-miR-3613-5p 的高表达与 KIRC 的进展有关。因此，它可能被认为是 KIRC 患者早期检测、风险分层和靶向治疗的有价值的指标。
